PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.21%
Revenue growth of 5.21% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
8.31%
Gross profit growth of 8.31% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
25.60%
Positive EBIT growth while Medical - Pharmaceuticals median is negative. Peter Lynch might see a strong competitive advantage in operations.
27.07%
Positive operating income growth while Medical - Pharmaceuticals is negative. Peter Lynch would spot a big relative advantage here.
40.70%
Positive net income growth while Medical - Pharmaceuticals median is negative. Peter Lynch would view this as a notable competitive advantage.
40.71%
Positive EPS growth while Medical - Pharmaceuticals median is negative. Peter Lynch might see a strong advantage in per-share earnings compared to peers.
40.71%
Positive diluted EPS growth while Medical - Pharmaceuticals median is negative. Peter Lynch might see a real advantage in how this firm manages share count or drives net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
51.58%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 32.07%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
-16.43%
Negative 5Y CAGR while Medical - Pharmaceuticals median is 20.46%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
39.52%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 12.47%. Joel Greenblatt might see a short-term competitive advantage at play.
-100.00%
Negative 10Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
146.54%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 0.76% over a decade. Joel Greenblatt might see a standout compounder of earnings.
26.35%
Net income/share CAGR of 26.35% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
62.87%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 4.94%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
172.32%
Equity/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 86.53% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
21.13%
Below 50% of Medical - Pharmaceuticals median. Jim Chanos suspects weak profitability or questionable capital allocation limiting equity growth.
67.38%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 30.05%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
-25.00%
Dividend declines over 10 years while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative disadvantage if peers consistently raised payouts.
50.00%
5Y dividend/share CAGR of 50.00% while Medical - Pharmaceuticals is zero. Walter Schloss sees at least some improvement that could compound over time.
38.46%
3Y dividend/share CAGR of 38.46% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
23035.00%
AR growth of 23035.00% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
10.52%
Inventory growth of 10.52% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
6.02%
Asset growth of 6.02% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
5.55%
BV/share growth of 5.55% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
1.97%
Debt growth of 1.97% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
-46.41%
SG&A decline while Medical - Pharmaceuticals grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.